Angiogenic Switch in Patients With Colorectal Cancer

Summary

A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .

Timeline

Start

2011-07

Primary completion

2015-05

Completion

2015-05

Drugs

Indications